Tumor blood vessels play an important role in radiation response, therefore the vascular targeted therapies targeting specific endothelial cell markers are promising approaches for the combined treatment modalities of cancer. One of the potential vascular targets is endoglin, transforming growth factor-β (TGF-β) co-receptor, which mediates angiogenesis of tumors. However, its specific, safe and long-lasting targeting remains the challenge. Therefore, in our preliminary study we firstly evaluated the transfection efficacy, vascular targeted effects and therapeutic potential of the plasmid silencing endoglin with tissue specific promoter specific for endothelial cells in comparison to the plasmid with constitutive promoter, in vitro and in vivo, and obtained promising results. Since the same efficacy as of GET of CON plasmid was determined by TS plasmid, further studies combining the latter plasmid and radiation should be performed.
COBISS.SI-ID: 1966203